BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fisher JE Jr. Considerations for the Nonclinical Safety Evaluation of Antibody-Drug Conjugates. Antibodies (Basel) 2021;10:15. [PMID: 33921632 DOI: 10.3390/antib10020015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cahuzac H, Sallustrau A, Malgorn C, Beau F, Barbe P, Babin V, Dubois S, Palazzolo A, Thai R, Correia I, Lee KB, Garcia-Argote S, Lequin O, Keck M, Nozach H, Feuillastre S, Ge X, Pieters G, Audisio D, Devel L. Monitoring In Vivo Performances of Protein-Drug Conjugates Using Site-Selective Dual Radiolabeling and Ex Vivo Digital Imaging. J Med Chem 2022;65:6953-68. [PMID: 35500280 DOI: 10.1021/acs.jmedchem.2c00401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hui X, Yuan C, Cao W, Ge W, Zhang D, Dan M, Zhao Q, Liu B, Yao B. An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index. OTT 2022;Volume 15:331-43. [DOI: 10.2147/ott.s357326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]